2022
Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice
Arthur CM, Patel SR, Sharma A, Zerra PE, Chonat S, Jajosky RP, Fasano RM, Patel R, Bennett A, Zhou X, Luckey CJ, Hudson KE, Eisenbarth SC, Josephson CD, Roback JD, Hendrickson JE, Stowell SR. Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion 2022, 62: 948-953. PMID: 35470900, PMCID: PMC9491148, DOI: 10.1111/trf.16872.Peer-Reviewed Original ResearchConceptsRBC alloimmunizationRBC transfusionAntibody formationPreclinical modelsRed blood cell transfusionBlood cell alloantigensBlood cell transfusionTransfusion of RBCsTransfusion-dependent patientsDevelopment of alloantibodiesIgG antibody formationAlloantigen exposureHOD RBCsCell transfusionPost transfusionAlloantibody formationPharmacological removalIgG antibodiesTransfusionAlloimmunizationClodronateMarginal sinusPrior treatmentDay 5KEL antigen
2019
Transfusion-related red blood cell alloantibodies: induction and consequences
Tormey CA, Hendrickson JE. Transfusion-related red blood cell alloantibodies: induction and consequences. Blood 2019, 133: 1821-1830. PMID: 30808636, PMCID: PMC6484385, DOI: 10.1182/blood-2018-08-833962.Peer-Reviewed Original ResearchConceptsTransfusion recipientsBlood donorsPreventative strategiesBlood product exposureCompatible RBC unitsRBC alloantibody formationHemolytic transfusion reactionsDevelopment of alloantibodiesAdaptive immune factorsJudicious transfusionRBC alloimmunizationImmunomodulatory therapyAlloantibody formationBlood transfusionRBC alloantibodiesRecipient variablesFuture pregnanciesImmune factorsTransfusion reactionsBlood productsHemolytic diseaseFuture transfusionsHuman studiesTransfusionAlloantibodies
2018
Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model.
Madrid DJ, Santhanakrishnan M, Liu J, Gibb DR, Liu D, Natarajan P, Beitler D, Shi Z, Mo C, Tormey CA, Patel SR, Stowell SR, Hendrickson JE. Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model. Blood Transfusion 2018, 17: 368-377. PMID: 30418129, PMCID: PMC6774925, DOI: 10.2450/2018.0178-18.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionBlood cell transfusionTransfusion of plateletsAlloimmune responseRed blood cellsCell transfusionWild-type recipientsBlood cellsImmune responseMurine modelRed blood cell alloimmunisationCD40/CD40L interactionHuman KEL glycoproteinWild-type C57BL/6Humoral immune responseAdaptive immune responsesDevelopment of alloantibodiesPlatelet-rich plasmaEndogenous plateletsCD40L interactionRecipient treatmentTransfusionDanger signalsCD40LTransgenic donors3 The Importance of CD4 Cells and CD40/CD40 Ligand Interactions in Humoral Immune Responses to Transfused KEL RBCs in Mice
Madrid D, Gibb D, Natarajan P, Santhanakrishnan M, Liu J, Hendrickson J. 3 The Importance of CD4 Cells and CD40/CD40 Ligand Interactions in Humoral Immune Responses to Transfused KEL RBCs in Mice. American Journal Of Clinical Pathology 2018, 149: s164-s164. DOI: 10.1093/ajcp/aqx149.372.Peer-Reviewed Original ResearchCD40/CD40 ligand interactionsCD40 ligand interactionsCD40/CD40L blockadeWild-type animalsRed blood cellsNonresponder animalsCD40L blockadeWeeks posttransfusionType animalsIgG antibodiesT cellsImmune responseMonoclonal antibodiesAbsence of CD4CD40 ligand blockadeHuman KEL glycoproteinFlow cytometric crossmatchHemolytic transfusion reactionsDurable immune responsesHumoral immune responseWild-type miceDevelopment of alloantibodiesT cell interactionsMurine red blood cellsAlloantibody responses
2016
Red Blood Cell Antibodies in Hematology/Oncology Patients Interpretation of Immunohematologic Tests and Clinical Significance of Detected Antibodies
Hendrickson JE, Tormey CA. Red Blood Cell Antibodies in Hematology/Oncology Patients Interpretation of Immunohematologic Tests and Clinical Significance of Detected Antibodies. Hematology/Oncology Clinics Of North America 2016, 30: 635-651. PMID: 27113001, DOI: 10.1016/j.hoc.2016.01.006.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionRed blood cell antibodiesRBC alloimmunization rateBlood cell transfusionManagement of patientsDevelopment of alloantibodiesBlood group antigensAlloimmunization rateRBC alloimmunizationSuch alloantibodiesCell transfusionCell antibodiesClinical significanceHemolytic anemiaPatients' interpretationsDetected antibodiesTransfusionGroup antigensBlood bankCompatible unitsAntibodiesAlloantibodiesOncology disordersDeleterious consequencesAlloimmunization
2015
A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization
Celli R, Schulz W, Hendrickson J, Tormey C. A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization. Blood 2015, 126: 2349. DOI: 10.1182/blood.v126.23.2349.2349.Peer-Reviewed Original ResearchDisease statesControl cohortAcute myeloid leukemia/myelodysplastic syndromeLeukemia/myelodysplastic syndromeRed blood cell alloimmunizationChronic transfusion supportHyper-responder groupAcute renal failureAML/MDSAcute myocardial infarctionICD-9 codesDevelopment of alloantibodiesSpecific medical conditionsElectronic medical recordsSignificant disease associationCertain disease statesAlloimmunized individualsRBC alloimmunizationGastrointestinal bleedPulmonary hypertensionRenal failureTransfusion burdenTransfusion supportMale patientsRBC transfusion
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply